Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk.
Joyner CD, Peters RJ, Afzal R, Chrolavicius S, Mehta SR, Fox KA, Granger CB, Franzosi MG, Flather M, Budaj A, Bassand JP, Yusuf S. Joyner CD, et al. Among authors: flather m. Am Heart J. 2009 Mar;157(3):502-8. doi: 10.1016/j.ahj.2008.10.028. Am Heart J. 2009. PMID: 19249421 Clinical Trial.
Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
Mehta SR, Boden WE, Eikelboom JW, Flather M, Steg PG, Avezum A, Afzal R, Piegas LS, Faxon DP, Widimsky P, Budaj A, Chrolavicius S, Rupprecht HJ, Jolly S, Granger CB, Fox KA, Bassand JP, Yusuf S; OASIS 5 and 6 Investigators. Mehta SR, et al. Among authors: flather m. Circulation. 2008 Nov 11;118(20):2038-46. doi: 10.1161/CIRCULATIONAHA.108.789479. Epub 2008 Oct 27. Circulation. 2008. PMID: 18955665 Clinical Trial.
Fondaparinux versus Enoxaparin in non-ST-elevation acute coronary syndromes: short-term cost and long-term cost-effectiveness using data from the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators (OASIS-5) trial.
Sculpher MJ, Lozano-Ortega G, Sambrook J, Palmer S, Ormanidhi O, Bakhai A, Flather M, Steg PG, Mehta SR, Weintraub W. Sculpher MJ, et al. Among authors: flather m. Am Heart J. 2009 May;157(5):845-52. doi: 10.1016/j.ahj.2009.02.017. Am Heart J. 2009. PMID: 19376310 Clinical Trial.
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.
Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ; RE-LY investigators. Wallentin L, et al. Among authors: flather m. Lancet. 2010 Sep 18;376(9745):975-83. doi: 10.1016/S0140-6736(10)61194-4. Lancet. 2010. PMID: 20801496 Clinical Trial.
Irbesartan in patients with atrial fibrillation.
ACTIVE I Investigators; Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ. ACTIVE I Investigators, et al. Among authors: flather m. N Engl J Med. 2011 Mar 10;364(10):928-38. doi: 10.1056/NEJMoa1008816. N Engl J Med. 2011. PMID: 21388310 Free article. Clinical Trial.
Large streamlined trials in cardiovascular disease.
Calvo G, McMurray JJ, Granger CB, Alonso-García Á, Armstrong P, Flather M, Gómez-Outes A, Pocock S, Stockbridge N, Svensson A, Van de Werf F. Calvo G, et al. Among authors: flather m. Eur Heart J. 2014 Mar;35(9):544-8. doi: 10.1093/eurheartj/eht535. Epub 2014 Jan 2. Eur Heart J. 2014. PMID: 24385376 No abstract available.
Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome.
Khan R, Lopes RD, Neely ML, Stevens SR, Harrington RA, Diaz R, Cools F, Jansky P, Montalescot G, Atar D, Lopez-Sendon J, Flather M, Liaw D, Wallentin L, Alexander JH, Goodman SG; Apixaban for Prevention of Acute Ischemic Safety Events (APPRAISE)-2 Steering Committee and Investigators. Khan R, et al. Among authors: flather m. Heart. 2015 Sep;101(18):1475-84. doi: 10.1136/heartjnl-2014-307346. Epub 2015 Jun 24. Heart. 2015. PMID: 26109589 Clinical Trial.
Infarct Size Following Treatment With Second- Versus Third-Generation P2Y12 Antagonists in Patients With Multivessel Coronary Disease at ST-Segment Elevation Myocardial Infarction in the CvLPRIT Study.
Khan JN, Greenwood JP, Nazir SA, Lai FY, Dalby M, Curzen N, Hetherington S, Kelly DJ, Blackman D, Peebles C, Wong J, Flather M, Swanton H, Gershlick AH, McCann GP. Khan JN, et al. Among authors: flather m. J Am Heart Assoc. 2016 May 31;5(6):e003403. doi: 10.1161/JAHA.116.003403. J Am Heart Assoc. 2016. PMID: 27247336 Free PMC article. Clinical Trial.
354 results